These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Results of chemoimmune prophylaxis of superficial bladder carcinoma (author's transl)]. Adolphs HD; Helpap B Urologe A; 1982 Jan; 21(1):29-33. PubMed ID: 7200654 [TBL] [Abstract][Full Text] [Related]
4. Management of superficial bladder carcinoma with BCG. Long term follow-up. Martínez-Piñeiro JA Prog Clin Biol Res; 1984; 162B():335-45. PubMed ID: 6438642 [No Abstract] [Full Text] [Related]
5. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer. van der Meijden AP Prog Clin Biol Res; 1992; 378():95-101. PubMed ID: 1301591 [No Abstract] [Full Text] [Related]
6. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer. Burk K; Kurth KH; Newling D Prog Clin Biol Res; 1989; 303():423-34. PubMed ID: 2780657 [No Abstract] [Full Text] [Related]
7. [Polyarthritis as a rare complication in BCG immunoprophylaxis of urinary bladder cancer]. Varentsov GI; Zakhmatov IuM; Kornev AI; Otvetchikov IN Urologiia; 1999; (5):29-30. PubMed ID: 11150151 [TBL] [Abstract][Full Text] [Related]
8. Results and follow-up of bladder tumors following transurethral resection. Gibbons RP Prog Clin Biol Res; 1984; 162A():359-73. PubMed ID: 6385028 [No Abstract] [Full Text] [Related]
9. Re: Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. Palou J; Rodríguez O; Segarra J; Rosales A J Urol; 2006 Jul; 176(1):407; author reply 407-8. PubMed ID: 16753451 [No Abstract] [Full Text] [Related]
10. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence]. Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813 [TBL] [Abstract][Full Text] [Related]
12. [BCG and radiotherapy: the compatibility of 2 conservative treatments for cancer of the urinary bladder]. Sánchez-Martín FM; Palou Redorta J; Regalado Pareja R; Rubio Briones J; Villavicencio Mavric H; Vicente Rodríguez J Arch Esp Urol; 1999 Sep; 52(7):749-58. PubMed ID: 10540765 [TBL] [Abstract][Full Text] [Related]
13. [The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG]. Shekarsarai H; Zlotta AR; Drowart A; Van Vooren JP; De Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K Acta Urol Belg; 1997 Mar; 65(1):1-4. PubMed ID: 9245197 [TBL] [Abstract][Full Text] [Related]
16. Chemoimmune prophylaxis of superficial bladder tumors: results after treatment of 130 patients in 4 years. Adolphs HD; Bastian HP Urol Res; 1983; 11(6):271-4. PubMed ID: 6362161 [TBL] [Abstract][Full Text] [Related]
17. Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols. Prout GR; Kopp J Prog Clin Biol Res; 1984; 162B():397-427. PubMed ID: 6438644 [No Abstract] [Full Text] [Related]
18. [Tumors of the upper urothelium and cyclophosphamide: presentation of a case and review of the literature]. de Castro Barbosa F; Rosell Costa D; Agüera Fernández L; Isa Kroon WA; Sánchez de la Muela P; Robles García JE; Zudaire Bergera JJ; Berián Polo JM Arch Esp Urol; 1991 Dec; 44(10):1149-51. PubMed ID: 1817448 [TBL] [Abstract][Full Text] [Related]